Cargando…
Cutaneous manifestations associated with immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of tumor-mediated immune evasion. The frequency of its use has increased rapidly and has extended to numerous cancers. ICIs target immune checkpoint molecules, such as programmed cell death protein 1 (PD-1), PD li...
Autores principales: | Watanabe, Tomoya, Yamaguchi, Yukie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986601/ https://www.ncbi.nlm.nih.gov/pubmed/36891313 http://dx.doi.org/10.3389/fimmu.2023.1071983 |
Ejemplares similares
-
A rare cutaneous manifestation of immune checkpoint inhibitor therapy
por: Cherneskie, John, et al.
Publicado: (2023) -
Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021) -
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
por: Cao, Ting, et al.
Publicado: (2023) -
Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021)